Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia

Xue Min Gao, Thomas Cooper, Raymond F. Suckow, Carol A. Tamminga

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Risperidone is a second-generation antipsychotic that lacks acute motor side effects at low doses (<6 mg/day), but above this level is associated with parkinsonism and akathesia. The literature suggests an association between acute motor side effects and tardive dyskinesia (TD); therefore, we hypothesized that low dose levels of risperidone will spare TD. As clinical studies of TD liability with fixed doses of risperidone are difficult to conduct, we tested low and high doses of risperidone in a rodent model of TD, vacuous chewing movements (VCMs) production. Low doses of risperidone (1.5 mg/kg/day) resulted in control levels of VCMs after 6 months of treatment, whereas high doses of risperidone (6 mg/kg/day) produced VCM in the same range as haloperidol. Plasma drug levels are reported. If this animal model predicts TD risk in humans, the TD liability with low-dose risperidone is at a placebo level, whereas higher doses show haloperidol-like TD risk, as predicted from the acute motor effects.

Original languageEnglish (US)
Pages (from-to)1864-1868
Number of pages5
Issue number9
StatePublished - Sep 12 2006


  • 5HT2A receptor
  • Antipsychotic
  • Haloperidol
  • Tardive dyskinesis
  • Vacuous chewing movement

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health


Dive into the research topics of 'Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia'. Together they form a unique fingerprint.

Cite this